Biocon Biologics is transforming patient outcomes by making life-changing therapies more accessible to the world. Through affordable biosimilars, we are reducing the global healthcare burden, increasing treatment options and driving innovation in biologics, to advance health equity, globally.

KNOW MORE

Our Differentiators

Integrated to Scale

Transform patients’ lives by delivering affordable access to innovative and inclusive healthcare solutions.

BIOCON LEGACY

Biocon’s rich legacy of being at the cutting edge of science is enabling us to enable health equity worldwide.

EXPANSIVE PORTFOLIO

An expansive portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins.

GLOBAL PRESENCE

A commercial footprint stretching to over 100 countries, which includes both advanced and emerging markets.

Our Impact

5.7 Million

Patients benefit from our biosimilars, annually

3.75 Billion

Doses of rh-insulin supplied to patients globally since 2004

20 Biosimilars

In the pipeline

8 Biosimilars

Commercialized in global markets

Our Firsts

  • 2004

    World’s 1st Pichia pastoris technology based rh-Insulin developed and commercialized in India

  • 2017

    1st company globally to get U.S. FDA approval for bTrastuzumab

  • 2018

    1st company globally to get U.S. FDA approval for bPegfilgrastim

  • 2021

    1st company globally to commercialize interchangeable bGlargine in U.S.

Our Commitment

Our Commitment

At Biocon Biologics, we are driven by a humanitarian purpose to make healthcare affordable and accessible to even the poorest of patients. This philosophy resonates with our Environmental, Social and Governance (ESG) practices, which stand on the five pillars of Patient Equity, People Equity, Environment Equity, Stakeholder Equity, Social Equity.

Know More

News

Nov 09, 2023

Know More

Leveraging THE POWER OF ONE

Biocon Biologics has acquired the global biosimilars business of Viatris to become a Unique, World-Class, Fully Integrated Biosimilars Leader

We are enabling affordable access to lifesaving biosimilars worldwide.

Know More Video >>
Share